Pleomorphic adenoma gene like-2 enhances the invasive ability of cancer cells in human colon adenocarcinoma

doi:10.3877/cma.j.issn.2095-3224.2018.02.006

Abstract

Abstract:

Objective

To investigate the expression of PLAGL2 in colon cancer tissues and adjacent normal tissues and its relationship with the clinicopathological factors of colon cancer, to study the function of PLAGL2 on invasive process of colon cancer cells and its mechanism.

Methods

The expressions of PLAGL2 were detected in 40 fresh colon cancer tissues and control normal tissues by immunohistochemistry. According to the results of preoperative imaging examinations and postoperative pathological staging of patients, the relationship between the expression of PLAGL2 and the clinicopathological factors was analyzed. After construction of the recombinant plasmid pcDNA3.1-PLAGL2, SW480 cells were transfected with the plasmid pcDNA3.1- PLAGL2 and empty vector using Lipofectamine? 2000. Three groups of cell line including SW480, Vector and PLAGL2 were cultured and compared the difference of invasive ability by Transwell assay. Finally, Western-blot detected the expression of E-cadherin, vimentin and MMP-7 among cell line of the three groups.

Results

The immunoreactivity scores of PLAGL2 in stage Ⅲ-Ⅳ, stage Ⅰ-Ⅱ and adjacent normal tissues were 8.12±2.997、5.71±2.494、2.17±0.984 respectively, indicating a statistically significant difference (F=64.225, P<0.01). Chi square test showed that the patients with PLAGL2-over expression had more advanced stages (χ²=5.700, P=0.017)、bigger sizes (χ²=8.174, P=0.008) and easier to happen metastasis (χ²=13.610, P<0.001). The invasion of the cells were significantly promoted in PLAGL2 group than other two groups by Transwell assay (F=27.997, P<0.01). Western-blot method for detection of PLAGL2 cells significantly decreased expression of E-cadherin (F=38.461, P<0.01) and increased the expression of vimentin (F=28.741, P<0.01) and MMP-7 (F=24.520, P<0.01), with statistically significant difference compared other two groups.

Conclusions

The upregulation of PLAGL2, which is closely correlated to the occurrence and development of colon cancer and can promote the invasive ability of colon cancer cells, may be related to the formation of EMT.

Key words: Colonic neoplasms, Pleomorphic adenoma gene like-2, Epithelial mesenchymal transition, Invasion

Xiujie Ding, Yongpeng Wang, Siping Ma, Rui Zhang, Yan Wang, Qingtong Zhang, Hao Zhang, Penglei Li, Tao Lin, Yanxi Li, Yuze Chen, Fang Liu. Pleomorphic adenoma gene like-2 enhances the invasive ability of cancer cells in human colon adenocarcinoma[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(02): 130-136.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2018.02.006

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2018/V07/I02/130

Figures/Tables 5

References 24

[1]	Siegel R, Desantis C, Jemal A. Colorectal cancer statistics [J]. CA Cancer J Clin, 2014, 64(2): 104-117.
[2]	El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines [J]. CA Cancer J Clin, 2015, 65(6): 428-455.
[3]	Viganò L, Capussotti L, Lapointe R, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6, 025 patients [J]. Ann Surg Oncol, 2014, 21(4): 1276-1286.
[4]	Cawkwell L, Lewis FA, Quirke P. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction [J]. Br J Cancer, 1994, 70(5): 813-818.
[5]	Ioana M, Angelescu C, Burada F, et al. MMR gene expression pattern in sporadic colorectal cancer [J]. J Gastrointestin Liver Dis, 2010, 19(2): 155-159.
[6]	Matsuzaki S, Darcha C, Pouly JL, et al. Effects of matrix stiffness on epithelial to mesenchymal transition-like processes of endometrial epithelial cells: Implications for the pathogenesis of endometriosis [J]. Sci Rep, 2017, 7:44616.
[7]	Furukawa T, Adachi Y, Fujisawa J, et al. Involvement of PLAGL2 in activation of iron deficient- and hypoxia-induced gene expression in mouse cell lines [J]. Oncogene, 2001, 20(34): 4718-4727.
[8]	Zheng H, Ying H, Wiedemeyer R, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas [J]. Cancer Cell, 2010, 17(5): 497-509.
[9]	Liu B, Lu C, Song YX, et al. The role of pleomorphic adenoma gene-like 2 in gastrointestinal cancer development, progression, and prognosis [J]. Int J Clin Exp Pathol, 2014, 7(6): 3089-3100.
[10]	Van Dyck F, Delvaux EL, Van de Ven WJ, et al. Repression of the transactivating capacity of the oncoprotein PLAG1 by SUMOylation [J]. J Biol Chem, 2004, 279(34): 36121-36131.
[11]	Lanzara C, Ficarella R, Totaro A, et al. Congenital dyserythropoietic anemia type II: Exclusion of seven candidate genes [J]. Blood Cells Mol Dis, 2003, 30(1): 22-29.
[12]	Kas K, Voz ML, Röijer E, et al. Promoter swapping between the genes for a novel zinc finger protein and beta-catenin in pleiomorphic adenomas with t(3;8)(p21;q12) translocations [J]. Nat Genet, 1997, 15(4): 170-174.
[13]	Thiery JP. Epithelial-mesenchymal transitions in tumour progression [J]. Nat Rev Cancer, 2002, 2(6): 442-454.
[14]	Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells [J]. Seminars in Cancer Biology, 2012, 22(3): 194-207.
[15]	Gu GL, Zhu XQ, Wei XM, et al. Epithelial-mesenchymal transition in colorectal cancer tissue of patients with Lynch syndrome [J]. World J Gastroenterol, 2014, 20(1): 250-257.
[16]	Khare V, Lang M, Dammann K, et al. Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells [J]. Biochem Pharmacol, 2014, 87(2): 312-320.
[17]	Roylance R, Droufakou S, Gorman P, et al. The role of E-cadherin in low-grade ductal breast tumourigenesis [J]. J Pathol, 2003, 200(1): 53-58.
[18]	Lv H, Liu R, Fu J, et al. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway [J]. Cell Cycle, 2014, 13(18): 2962-2974.
[19]	Kim CH, Park SY, Yoo J. Expression of Transforming Growth Factor β1 and E-Cadherin Proteins in Pulmonary Adenocarcinoma: Its Significance in Tumor Progression [J]. Cancer Res Treat, 2013, 45(2): 118-125.
[20]	Calangiu CM, Simionescu CE, Stepan AE, et al. The expression of CK19, vimentin and E-cadherin in differentiated thyroid carcinomas [J]. Rom J Morphol Embryol, 2014, 55(3): 919-925.
[21]	Shirahata A, Sakata M, Sakuraba K, et al. Vimentin methylation as a marker for advanced colorectal carcinoma [J]. Anticancer Res, 2009, 29(1): 279-281.
[22]	Miyake T, Yasukawa K, Inouye K. Analysis of the mechanism of inhibition of human matrix metalloproteinase 7 (MMP-7) activity by green tea catechins [J]. Biosci Biotechnol Biochem, 2011, 75(8): 1564-1569.
[23]	Letra A, Ghaneh G, Zhao M, et al. MMP-7 and TIMP-1, new targets in predicting poor wound healing in apical periodontitis [J]. J Endod, 2013, 39(9): 1141-1146.
[24]	Sun DW, Zhang YY, Qi Y, et al. Prognostic significance of MMP-7 expression in colorectal cancer: A meta-analysis [J]. Cancer Epidemiol, 2015, 39(2): 135-142.

分组	例数	IS值（Mean±SD）
癌旁组织	40	2.170±0.984
Ⅰ~Ⅱ期结肠癌组织	14	5.710±2.494
Ⅲ~Ⅳ期结肠癌组织	26	8.120±2.997
整体比较F，P	?	64.225，<0.001
多重比较LSD-t，P	癌旁组织vs.Ⅰ~Ⅱ期	3.564，<0.001
?	癌旁组织vs.Ⅲ~Ⅳ期	5.965，<0.001
?	Ⅰ~Ⅱ期vs.Ⅲ~Ⅳ期	2.401，0.020

分组	例数	IS值（Mean±SD）
癌旁组织	40	2.170±0.984
Ⅰ~Ⅱ期结肠癌组织	14	5.710±2.494
Ⅲ~Ⅳ期结肠癌组织	26	8.120±2.997
整体比较F，P	?	64.225，<0.001
多重比较LSD-t，P	癌旁组织vs.Ⅰ~Ⅱ期	3.564，<0.001
?	癌旁组织vs.Ⅲ~Ⅳ期	5.965，<0.001
?	Ⅰ~Ⅱ期vs.Ⅲ~Ⅳ期	2.401，0.020

临床病理因素		例数	PLAGL2表达水平		χ²值	P值
临床病理因素		例数	低表达	高表达	χ²值	P值
年龄（岁）		?	?	?	0.317	0.729
?	≥55	24	8	16	?	?
?	<55	16	4	12	?	?
肿瘤大小		?	?	?	8.174	0.008
?	≥3 cm	29	5	24	?	?
?	<3 cm	11	7	4	?	?
临床分期		?	?	?	5.700	0.017
?	I~II	14	8	6	?	?
?	III~IV	26	4	22	?	?
组织学类型		?	?	?	?	0.997*
?	腺癌	25	8	17	?	?
?	黏液腺癌	11	3	8	?	?
?	未分化癌	4	1	3	?	?

临床病理因素		例数	PLAGL2表达水平		χ²值	P值
临床病理因素		例数	低表达	高表达	χ²值	P值
年龄（岁）		?	?	?	0.317	0.729
?	≥55	24	8	16	?	?
?	<55	16	4	12	?	?
肿瘤大小		?	?	?	8.174	0.008
?	≥3 cm	29	5	24	?	?
?	<3 cm	11	7	4	?	?
临床分期		?	?	?	5.700	0.017
?	I~II	14	8	6	?	?
?	III~IV	26	4	22	?	?
组织学类型		?	?	?	?	0.997*
?	腺癌	25	8	17	?	?
?	黏液腺癌	11	3	8	?	?
?	未分化癌	4	1	3	?	?

Please choose a citation manager

Content to export